Abstract
Osteomyelitis, especially its chronic form, con tinues to be a difficult infection to manage, with great diagnostic and therapeutic problems. Signifi cant changes have taken place in the epidemiology, microbiology and antibiotic therapy of bone infec tion. Staphylococcus aureus remains the most com mon causative microorganism of osteomyelitis, although Gram-negative bacilli in their totality overcome it, particularly in some specific forms of osteomyelitis. Pefloxacin is a new fluoroquinolone with a broad spectrum of activity, which includes Gram-negative bacilli and staphylococci. It can be administered both orally and intravenously, and is associated with high bioavailability and good bone diffusion, a long half-life and few secondary effects (Gonzalez & Henwood 1989).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
